Charles W. Newton Buys 200,000 Shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) CFO Charles W. Newton purchased 200,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average price of $0.56 per share, for a total transaction of $112,000.00. Following the acquisition, the chief financial officer now owns 200,000 shares in the company, valued at approximately $112,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Lyell Immunopharma Stock Performance

Shares of LYEL traded up $0.05 during trading hours on Friday, hitting $0.58. The stock had a trading volume of 1,287,155 shares, compared to its average volume of 1,048,095. Lyell Immunopharma, Inc. has a 12-month low of $0.48 and a 12-month high of $3.15. The firm has a market cap of $170.79 million, a P/E ratio of -0.73 and a beta of -0.41. The company's fifty day simple moving average is $0.61 and its 200 day simple moving average is $0.88.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The firm had revenue of $0.01 million during the quarter. As a group, sell-side analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Remove Ads

Institutional Investors Weigh In On Lyell Immunopharma

Several institutional investors have recently bought and sold shares of the business. Public Employees Retirement System of Ohio acquired a new position in shares of Lyell Immunopharma during the 4th quarter valued at $64,000. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma during the fourth quarter valued at approximately $4,545,000. Two Sigma Advisers LP lifted its position in shares of Lyell Immunopharma by 143.8% during the fourth quarter. Two Sigma Advisers LP now owns 306,400 shares of the company's stock worth $196,000 after purchasing an additional 180,700 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Lyell Immunopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company's stock valued at $613,000 after purchasing an additional 247,440 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Lyell Immunopharma by 13.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company's stock valued at $197,000 after purchasing an additional 36,555 shares in the last quarter. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a "neutral" rating and set a $1.00 price objective on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.